InvestmentPitch Media Video Discusses FSD Pharma’s Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MS
09 févr. 2023 06h00 HE
|
InvestmentPitch Media and FSD Pharma
VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets...